PeptideMeter result on a Qingdao cagrilintide lot lands 1.4 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Harriet Oduya
Page 5 of 10 of this archive, newest first.
Archive — page 5
192 piecesThe dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Percentage of loss, absolute kilograms, and the sleight of hand between them
What was pre-specified, what was exploratory, and what was calculated afterwards by people who did not run the trial.
SURPASS-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Twenty-eight days is a number from somebody else’s product
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A vial can be 99.4 per cent pure and not sterile in the same afternoon
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
SURPASS-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The withdrawal trials, read as designs rather than warnings
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
STEP 8 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a ERP survodutide lot at 96.4%, against 93.7% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
What SURMOUNT-1 tells us about maintenance, and what it does not
The commonest real-world strategy in this drug class is the least studied one.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Two-thirds back: the extension nobody expected to be the headline
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Independent analysis puts a KP liraglutide lot at 97.9%, against 97.0% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The shortage years, and what they taught about interruption
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Two sessions a week, and the evidence behind the prescription
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.